

## Supplementary Online Content

Sargen MR, Cahoon EK, Yu KJ, et al. Spectrum of nonkeratinocyte skin cancer risk among solid organ transplant recipients in the US. *JAMA Dermatol*. Published online March 9, 2022. doi:10.1001/jamadermatol.2022.0036

**eTable 1.** Cancer ICD-O-3 Histology/Behavior Codes

**eTable 2.** Unadjusted Risk Estimates for Melanoma, Merkel Cell Carcinoma, and Adnexal Cancers in Transplant Recipients

**eTable 3.** Unadjusted Risk Estimates for Kaposi Sarcoma and Lymphoma in Transplant Recipients

**eTable 4.** Transplant Donor and Recipient EBV Serologic Status at Time of Transplant and Lymphoma Risk

**eTable 5.** Baseline Induction and Maintenance Immunosuppressive Therapy and Risk for Melanoma, Merkel Cell Carcinoma, and Adnexal Cancers in Transplant Recipients

**eTable 6.** Baseline Induction and Maintenance Immunosuppressive Therapy and Risk for Kaposi Sarcoma and Lymphoma in Transplant Recipients

**This supplementary material has been provided by the authors to give readers additional information about their work.**

**eTable 1. Cancer ICD-O-3 histology/behavior codes**

<b>Cancer type</b>	<b>ICD-O-3 histology/behavior code</b>
<b>Melanoma</b>	8720/3, 8721/3, 8722/3, 8723/3, 8726/3, 8730/3, 8740/3, 8741/3, 8742/3, 8743/3, 8744/3, 8745/3, 8761/3, 8770/3, 8771/3, 8772/3, 8773/3, 8774/3, 8780/3, 8790/3
Superficial spreading melanoma	8743/3
Lentigo maligna melanoma	8742/3
Nodular melanoma	8721/3
Acral lentiginous melanoma	8744/3
Desmoplastic melanoma	8745/3
Amelanotic melanoma	8730/3
Other melanoma subtypes or not specified	8720/3, 8722/3, 8723/3, 8726/3, 8740/3, 8741/3, 8761/3, 8770/3, 8771/3, 8772/3, 8773/3, 8774/3, 8780/3, 8790/3
<b>Merkel cell carcinoma</b>	8247/3
<b>Adnexal cancers</b>	8200/3, 8390/3, 8400/3, 8401/3, 8402/3, 8407/3, 8408/3, 8409/3, 8410/3, 8413/3, 8480/3
Sebaceous carcinoma	8410/3
Ecrrine carcinoma	8200/3, 8390/3, 8400/3, 8401/3, 8402/3, 8407/3, 8408/3, 8409/3, 8413/3, 8480/3
Sweat gland adenocarcinoma	8400/3
Nodular hidradenoma, malignant	8402/3
Sclerosing sweat duct carcinoma	8407/3
Ecrrine papillary adenocarcinoma	8408/3
Ecrrine poroma, malignant	8409/3
Ecrrine adenocarcinoma	8413/3
Mucinous adenocarcinoma	8480/3
Apocrine adenocarcinoma	8401/3
Adenoid cystic carcinoma	8200/3
Skin appendage carcinoma	8390/3
<b>Sarcomas</b>	8710/3, 8711/3, 8832/3, 8833/3, 8890/3, 8891/3, 8893/3, 8896/3, 9120/3, 9125/3, 9140/3, 9170/3
Dermatofibrosarcoma Protuberans	8832/3, 8833/3
Cutaneous Leiomyosarcoma	8890/3, 8891/3, 8893/3, 8896/3
Cutaneous Angiosarcoma	9120/3, 9125/3, 9170/3
Glomangiosarcoma	8710/3, 8711/3
<b>Kaposi sarcoma</b>	9140/3
<b>Lymphoma</b>	9680/3, 9700/3, 9701/3, 9708/3, 9709/3, 9718/3, 9719/3

T-cell lymphoma	9700/3, 9701/3, 9708/3, 9709/3, 9718/3, 9719/3
Mycosis fungoides	9700/3
Sézary syndrome	9701/3
Anaplastic large cell lymphoma	9718/3
Subcutaneous panniculitis-like T-cell lymphoma	9708/3
Extranodal NK/T-cell lymphoma, nasal type	9719/3
Peripheral T-cell lymphoma, not otherwise specified	9709/3
Diffuse large B-cell lymphoma	9680/3

**eTable 2. Unadjusted risk estimates for melanoma, Merkel cell carcinoma, and adnexal cancers in transplant recipients**

Characteristic	Melanoma			Merkel cell carcinoma			Sebaceous carcinoma			Nonsebaceous adnexal cancers		
	No.	IRR (95% CI)	P	No.	IRR (95% CI)	P	No.	IRR (95% CI)	P	No.	IRR (95% CI)	P
<b>Total</b>	1,471			334			170			84		
<b>Sex</b>												
Female	334	Reference		72	Reference		36	Reference		24	Reference	
Male	1,137	2.19 (1.94-2.48)	<0.001	262	2.35 (1.81-3.04)	<0.001	134	2.40 (1.66-3.47)	<0.001	60	1.61 (1.00-2.59)	0.05
<b>Race and ethnicity</b>												
Non-Hispanic White	1,419	Reference		303	Reference		127	Reference		76	Reference	
Non-Hispanic Black	15	0.04 (0.03-0.07)	<0.001	5	0.07 (0.03-0.16)	<0.001	9	0.28 (0.14-0.55)	<0.001	2	0.10 (0.03-0.43)	0.002
Hispanic or Latino	31	0.10 (0.07-0.14)	<0.001	21	0.31 (0.20-0.48)	<0.001	23	0.81 (0.52-1.26)	0.35	4	0.24 (0.09-0.64)	0.005
Asian or Pacific Islander	6	0.05 (0.02-0.11)	<0.001	5	0.20 (0.08-0.47)	<0.001	11	1.02 (0.55-1.90)	0.94	2	0.31 (0.08-1.27)	0.10
<b>Age at transplant, years</b>												
0-34	77	Reference		9	Reference		4	Reference		4	Reference	
35-49	292	2.77 (2.15-3.56)	<0.001	69	5.60 (2.80-11.2)	<0.001	36	6.57 (2.34-18.5)	<0.001	17	3.10 (1.04-9.22)	0.04
50-64	776	6.10 (4.83-7.71)	<0.001	177	11.9 (6.09-23.3)	<0.001	95	14.4 (5.29-39.1)	<0.001	45	6.81 (2.45-18.9)	<0.001
≥65	326	11.0 (8.58-14.1)	<0.001	79	22.8 (11.4-45.5)	<0.001	35	22.7 (8.08-64.0)	<0.001	18	11.7 (3.96-34.5)	<0.001
P for trend			<0.001			<0.001			<0.001			<0.001
<b>Transplanted organ</b>												
Kidney	814	Reference		206	Reference		97	Reference		54	Reference	
Liver	273	0.87 (0.76-1.00)	0.05	46	0.58 (0.42-0.80)	0.001	21	0.56 (0.35-0.90)	0.02	10	0.48 (0.25-0.95)	0.03
Heart and/or lung	315	1.53 (1.35-1.75)	<0.001	72	1.39 (1.06-1.81)	0.02	47	1.92 (1.36-2.72)	<0.001	19	1.40 (0.83-2.35)	0.21
Other or multiple	69	0.90 (0.71-1.15)	0.41	10	0.52 (0.27-0.97)	0.04	5	0.55 (0.22-1.35)	0.19	1	0.20 (0.03-1.43)	0.11
<b>Calendar year of transplant</b>												
1987-1994	204	Reference		80	Reference		19	Reference		18	Reference	
1995-2002	533	0.90 (0.77-1.06)	0.20	113	0.49 (0.37-0.65)	<0.001	68	1.23 (0.74-2.05)	0.42	28	0.54 (0.30-0.97)	0.04
2003-2010	558	0.97 (0.82-1.13)	0.66	116	0.51 (0.38-0.68)	<0.001	67	1.24 (0.75-2.07)	0.40	31	0.61 (0.34-1.09)	0.09

2011-2017	176	0.95 (0.77-1.16)	0.58	25	0.34 (0.22-0.54)	<0.001	16	0.92 (0.47-1.79)	0.81	7	0.43 (0.18-1.02)	0.06
<b>Posttransplant basal cell carcinoma</b>												
No	1,378	Reference		294	Reference		156	Reference		74	Reference	
Yes	93	4.50 (3.65-5.55)	<0.001	40	9.07 (6.52-12.6)	<0.001	14	5.98 (3.46-10.3)	<0.001	10	9.01 (4.66-17.4)	<0.001
<b>Posttransplant squamous cell carcinoma</b>												
No	1,362	Reference		270	Reference		144	Reference		69	Reference	
Yes	109	3.94 (3.24-4.79)	<0.001	64	11.7 (8.88-15.3)	<0.001	26	8.88 (5.85-13.5)	<0.001	15	10.7 (6.12-18.7)	<0.001
<b>Annual mean daily UVR exposure<sup>a</sup></b>												
Quartile 1	389	Reference		84	Reference		56	Reference		18	Reference	
Quartile 2	390	0.84 (0.73-0.97)	0.02	75	0.75 (0.55-1.03)	0.07	35	0.53 (0.34-0.80)	0.003	18	0.84 (0.44-1.62)	0.60
Quartile 3	382	0.91 (0.79-1.05)	0.21	88	0.98 (0.72-1.32)	0.87	45	0.75 (0.51-1.11)	0.15	21	1.09 (0.58-2.04)	0.80
Quartile 4	310	0.81 (0.70-0.94)	0.005	87	1.05 (0.78-1.42)	0.75	34	0.61 (0.40-0.94)	0.03	27	1.52 (0.84-2.76)	0.17
<i>P</i> for trend			0.02			0.39			0.08			0.10
<b>Time since transplant</b>												
Within 1 year	155	Reference		18	Reference		3	Reference		4	Reference	
1 to 4.9 years	625	1.33 (1.12-1.59)	0.001	104	1.91 (1.16-3.15)	0.01	57	6.28 (1.97-20.1)	0.002	27	2.23 (0.78-6.38)	0.13
5 to 9.9 years	448	1.45 (1.21-1.75)	<0.001	124	3.47 (2.11-5.68)	<0.001	60	10.1 (3.16-32.1)	<0.001	35	4.40 (1.56-12.4)	0.005
≥10 years	243	1.51 (1.23-1.84)	<0.001	88	4.70 (2.83-7.80)	<0.001	50	16.0 (5.00-51.3)	<0.001	18	4.32 (1.46-12.8)	0.008
<i>P</i> for trend			<0.001			<0.001			<0.001			<0.001
<b>Transplant number</b>												
First	1,358	Reference		298	Reference		154	Reference		76	Reference	
Second or later	113	0.91 (0.75-1.10)	0.33	36	1.32 (0.93-1.86)	0.12	16	1.13 (0.68-1.90)	0.63	8	1.15 (0.55-2.38)	0.71

Abbreviations:

IRR – Incidence rate ratio

CI – Confidence interval

UVR – UV radiation

<sup>a</sup> Quartile cutoffs for ambient UVR (4.6-26.3, 26.4-34.2, 34.3-45.5, and 45.6-84.1 mW/m<sup>2</sup>) were based on the UVR (UV-B, 305nm) distribution among the transplant population.

**eTable 3. Unadjusted risk estimates for Kaposi sarcoma and lymphoma in transplant recipients**

Characteristic	Kaposi sarcoma			B- or T-cell lymphoma		
	No.	IRR (95% CI)	<i>P</i>	No.	IRR (95% CI)	<i>P</i>
<b>Total</b>	186			108		
<b>Sex</b>						
Female	38	Reference		40	Reference	
Male	148	2.51 (1.76-3.59)	<0.001	68	1.10 (0.74-1.62)	0.65
<b>Race and ethnicity</b>						
Non-Hispanic White	84	Reference		74	Reference	
Non-Hispanic Black	43	2.03 (1.41-2.94)	<0.001	13	0.70 (0.39-1.26)	0.23
Hispanic or Latino	52	2.77 (1.96-3.91)	<0.001	17	1.03 (0.61-1.74)	0.92
Asian or Pacific Islander	7	0.99 (0.46-2.13)	0.97	4	0.64 (0.23-1.75)	0.38
<b>Age at transplant, years</b>						
0-34	11	Reference		21	Reference	
35-49	26	1.73 (0.85-3.49)	0.13	30	1.04 (0.60-1.82)	0.88
50-64	96	5.28 (2.83-9.86)	<0.001	41	1.18 (0.70-2.00)	0.53
≥65	53	12.5 (6.54-24.0)	<0.001	16	1.98 (1.03-3.79)	0.04
<i>P</i> for trend			<0.001			0.07
<b>Transplanted organ</b>						
Kidney	123	Reference		63	Reference	
Liver	33	0.70 (0.48-1.03)	0.07	18	0.74 (0.44-1.26)	0.27
Heart and/or lung	26	0.84 (0.55-1.28)	0.41	24	1.51 (0.94-2.42)	0.09
Other or multiple	4	0.35 (0.13-0.94)	0.04	3	0.51 (0.16-1.61)	0.25
<b>Calendar year of transplant</b>						
1987-1994	19	Reference		29	Reference	
1995-2002	86	1.56 (0.95-2.56)	0.08	37	0.44 (0.27-0.72)	0.001
2003-2010	51	0.95 (0.56-1.60)	0.84	30	0.36 (0.22-0.61)	<0.001
2011-2017	30	1.73 (0.97-3.07)	0.06	12	0.45 (0.23-0.89)	0.02
<b>Posttransplant basal cell carcinoma</b>						
No	184	Reference		106	Reference	
Yes	2	0.72 (0.18-2.92)	0.65	2	1.26 (0.31-5.10)	0.75
<b>Posttransplant squamous cell carcinoma</b>						
No	186	Reference		104	Reference	
Yes	0	No estimate		4	1.89 (0.70-5.14)	0.21
<b>Annual mean daily UVR exposure<sup>a</sup></b>						
Quartile 1	27	Reference		31	Reference	
Quartile 2	64	1.99 (1.27-3.13)	0.003	22	0.60 (0.35-1.03)	0.06

Quartile 3	33	1.14 (0.68-1.89)	0.62	26	0.78 (0.46-1.32)	0.35
Quartile 4	62	2.33 (1.48-3.65)	<0.001	29	0.95 (0.57-1.57)	0.84
<i>P</i> for trend			0.007			0.93
<b>Time since transplant</b>						
Within 1 year	73	Reference		13	Reference	
1 to 4.9 years	94	0.43 (0.31-0.58)	<0.001	36	0.92 (0.49-1.73)	0.78
5 to 9.9 years	14	0.10 (0.05-0.17)	<0.001	37	1.43 (0.76-2.69)	0.27
≥10 years	5	0.07 (0.03-0.16)	<0.001	22	1.63 (0.82-3.23)	0.17
<i>P</i> for trend			<0.001			0.03
<b>Transplant number</b>						
First	176	Reference		99	Reference	
Second or later	10	0.62 (0.33-1.17)	0.14	9	0.99 (0.50-1.96)	0.98

Abbreviations:

IRR – Incidence rate ratio

CI – Confidence interval

UVR – UV radiation

<sup>a</sup> Quartile cutoffs for ambient UVR (4.6-26.3, 26.4-34.2, 34.3-45.5, and 45.6-84.1 mW/m<sup>2</sup>) were based on the UVR (UV-B, 305nm) distribution among the transplant population.

**eTable 4. Transplant donor and recipient EBV serologic status at time of transplant and lymphoma risk**

Characteristic	B or T-cell lymphoma			Diffuse large B-cell lymphoma			T-cell lymphoma			EBV-associated lymphoma <sup>a</sup>		
	No.	IRR (95% CI)	P	No.	IRR (95% CI)	P	No.	IRR (95% CI)	P	No.	IRR (95% CI)	P
Recipient (R) status <sup>b</sup>												
Negative	9	Reference		1	Reference		8	Reference		1	Reference	
Positive	30	0.70 (0.33-1.48)	0.35	3	0.63 (0.07-6.06)	0.69	27	0.71 (0.32-1.56)	0.39	4	0.84 (0.09-7.52)	0.88
Combined recipient (R) and donor (D) status <sup>c</sup>												
R negative/D negative	1	Reference		0	Reference		1	Reference		0	Reference	
R positive/D negative, positive or unknown	30	0.52 (0.07-3.78)	0.51	3	No estimate <sup>d</sup>		27	0.46 (0.06-3.41)	0.45	4	No estimate <sup>d</sup>	
R negative/D positive	4	0.70 (0.08-6.26)	0.75	1	No estimate <sup>d</sup>		3	0.52 (0.05-5.05)	0.58	1	No estimate <sup>d</sup>	

Abbreviations:

IRR – Incidence rate ratio

CI – Confidence interval

EBV – Epstein-Barr virus

<sup>a</sup> This category includes extranodal NK/T-cell lymphoma and diffuse large B-cell lymphoma.

<sup>b</sup> Recipient EBV serologic status was unknown for 69 (64% of cases) B or T-cell lymphomas, 19 (83% of cases) diffuse large B-cell lymphomas, 50 (59% of cases) T-cell lymphomas, and 20 (80% of cases) EBV-associated lymphomas.

<sup>c</sup> Combined donor and recipient EBV serologic status was unknown for 73 (68% of cases) B or T-cell lymphomas, 19 (83% of cases) diffuse large B-cell lymphomas, 54 (64% of cases) T-cell lymphomas, and 20 (80% of cases) EBV-associated lymphomas.

<sup>d</sup> The incidence rate ratio could not be calculated because of a zero value in the denominator.



**eTable 5. Baseline induction and maintenance immunosuppressive therapy and risk for melanoma, Merkel cell carcinoma, and adnexal cancers in transplant recipients**

Characteristic	Melanoma			Merkel cell carcinoma			Sebaceous carcinoma			Nonsebaceous adnexal cancers		
	No.	IRR (95% CI)	P	No.	IRR (95% CI)	P	No.	IRR (95% CI)	P	No.	IRR (95% CI)	P
<b>Total</b>	1,471			334			170			84		
<b>Medication exposures</b>												
<b>Induction therapy</b>												
Corticosteroids	907	1.03 (0.92-1.14)	0.63	194	0.88 (0.71-1.10)	0.27	105	1.03 (0.76-1.40)	0.85	49	0.89 (0.58-1.38)	0.61
Polyclonal antibody	315	0.96 (0.85-1.09)	0.53	67	0.89 (0.68-1.16)	0.37	50	1.47 (1.06-2.04)	0.02	19	1.03 (0.62-1.72)	0.91
Monoclonal antibody (OKT3)	71	1.05 (0.83-1.33)	0.69	8	0.51 (0.25-1.02)	0.06	5	0.63 (0.26-1.53)	0.30	5	1.31 (0.53-3.23)	0.56
Campath	54	1.08 (0.82-1.42)	0.58	12	1.06 (0.59-1.88)	0.85	8	1.40 (0.69-2.85)	0.35	5	1.79 (0.73-4.43)	0.21
IL-2 receptor antagonist	296	1.10 (0.97-1.25)	0.15	69	1.13 (0.87-1.48)	0.35	34	1.09 (0.75-1.59)	0.66	16	1.03 (0.59-1.77)	0.93
Rituximab	4	1.11 (0.42-2.96)	0.83	0	No Estimate		0	No Estimate		0	No Estimate	
<b>Maintenance therapy</b>												
Azathioprine	305	1.17 (1.03-1.33)	0.01	91	1.68 (1.32-2.13)	<0.001	37	1.25 (0.87-1.79)	0.24	16	1.05 (0.61-1.82)	0.85
Cyclosporine	572	1.20 (1.08-1.33)	0.001	136	1.29 (1.04-1.61)	0.02	60	1.03 (0.75-1.41)	0.87	36	1.41 (0.92-2.18)	0.12
Mycophenolate mofetil	929	1.08 (0.97-1.20)	0.15	169	0.65 (0.52-0.80)	<0.001	111	1.19 (0.87-1.63)	0.29	43	0.66 (0.43-1.02)	0.06
Mammalian target of rapamycin inhibitor	58	0.72 (0.55-0.93)	0.01	27	1.54 (1.04-2.28)	0.03	10	1.09 (0.58-2.07)	0.78	7	1.59 (0.73-3.45)	0.24
Corticosteroids	1,255	1.02 (0.88-1.18)	0.80	289	1.13 (0.82-1.54)	0.46	149	1.24 (0.79-1.96)	0.35	73	1.16 (0.62-2.19)	0.64
Tacrolimus	728	0.82 (0.74-0.91)	<0.001	152	0.70 (0.57-0.87)	0.001	96	1.09 (0.81-1.48)	0.57	36	0.63 (0.41-0.97)	0.04

<b>Combination therapy</b>												
Tacrolimus or mycophenolate mofetil without cyclosporine or azathioprine	689	Reference		134	Reference		88	Reference		33	Reference	
Cyclosporine or azathioprine without tacrolimus or mycophenolate mofetil	780	1.03 (0.93-1.14)	0.53	200	1.36 (1.09-1.70)	0.006	82	0.85 (0.63-1.15)	0.29	51	1.41 (0.91-2.19)	0.12
Other medication combinations	2	0.26 (0.06-1.02)	0.05	0	No Estimate		0	No Estimate		0	No Estimate	
<b>Medication exposures adjusted for calendar year of transplant</b>												
<b>Induction therapy</b>												
Corticosteroids	907	1.05 (0.94-1.17)	0.41	194	1.03 (0.82-1.30)	0.79	105	1.00 (0.73-1.37)	1.00	49	1.01 (0.64-1.59)	0.96
Polyclonal antibody	315	0.95 (0.84-1.08)	0.44	67	0.99 (0.75-1.30)	0.93	50	1.53 (1.08-2.15)	0.02	19	1.11 (0.66-1.89)	0.69
Monoclonal antibody (OKT3)	71	1.07 (0.84-1.36)	0.60	8	0.42 (0.21-0.86)	0.02	5	0.62 (0.25-1.53)	0.30	5	1.20 (0.47-3.02)	0.71
Campath	54	1.06 (0.81-1.40)	0.66	12	1.25 (0.69-2.26)	0.46	8	1.43 (0.69-2.96)	0.33	5	2.04 (0.80-5.20)	0.14
IL-2 receptor antagonist	296	1.11 (0.97-1.26)	0.13	69	1.38 (1.04-1.82)	0.03	34	1.07 (0.73-1.57)	0.72	16	1.16 (0.66-2.05)	0.60
Rituximab	4	1.09 (0.41-2.92)	0.86	0	No Estimate		0	No Estimate		0	No Estimate	
<b>Maintenance therapy</b>												
Azathioprine	305	1.25 (1.06-1.46)	0.007	91	1.19 (0.86-1.63)	0.29	37	1.53 (0.98-2.39)	0.06	16	0.64 (0.32-1.29)	0.21
Cyclosporine	572	1.33 (1.17-1.51)	<0.001	136	0.96 (0.73-1.26)	0.77	60	1.06 (0.73-1.56)	0.75	36	1.27 (0.73-2.20)	0.39

Mycophenolate mofetil	929	1.14 (1.00-1.30)	0.05	16 9	0.84 (0.64-1.11)	0.22	11 1	1.22 (0.84-1.78)	0.3 0	43	0.76 (0.45-1.30)	0.3 2
of Mammalian target rapamycin inhibitor	58	0.72 (0.55-0.94)	0.02	27	1.74 (1.17-2.60)	0.006	10	1.05 (0.55-1.99)	0.8 9	7	1.74 (0.79-3.82)	0.1 7
Corticosteroids	1,25 5	1.03 (0.89-1.20)	0.68	28 9	1.03 (0.75-1.43)	0.84	14 9	1.25 (0.79-2.00)	0.3 4	73	1.12 (0.58-2.14)	0.7 4
Tacrolimus	728	0.77 (0.68-0.86)	<0.00 1	15 2	0.83 (0.64-1.07)	0.15	96	1.07 (0.75-1.51)	0.7 2	36	0.64 (0.38-1.07)	0.0 9
<b>Combination therapy</b>												
Tacrolimus or mycophenolate mofetil without cyclosporine or azathioprine	689	Reference		13 4	Reference		88	Reference		33	Reference	
Cyclosporine or azathioprine without tacrolimus or mycophenolate mofetil	780	1.07 (0.94-1.21)	0.32	20 0	1.06 (0.80-1.41)	0.68	82	0.78 (0.54-1.14)	0.2 0	51	1.30 (0.75-2.27)	0.3 5
Other medication combinations	2	0.26 (0.07-1.05)	0.06	0	No Estimate		0	No Estimate		0	No Estimate	

Abbreviations:

IRR – Incidence rate ratio

CI – Confidence interval

**eTable 6. Baseline induction and maintenance immunosuppressive therapy and risk for Kaposi sarcoma and lymphoma in transplant recipients**

Characteristic	Kaposi sarcoma			B- or T-cell lymphoma		
	No	IRR (95% CI)	P	No.	IRR (95% CI)	P
<b>Total</b>	186			108		
<b>Medication exposures</b>						
<b>Induction therapy</b>						
Corticosteroids	116	1.06 (0.79-1.42)	0.71	68	1.08 (0.73-1.60)	0.68
Polyclonal antibody	41	1.00 (0.71-1.41)	0.99	22	0.90 (0.56-1.44)	0.67
Monoclonal antibody (OKT3)	6	0.69 (0.31-1.56)	0.37	11	2.35 (1.26-4.38)	0.007
Campath	3	0.46 (0.15-1.45)	0.19	4	1.09 (0.40-2.96)	0.87
IL-2 receptor antagonist	42	1.27 (0.90-1.79)	0.17	20	0.99 (0.61-1.61)	0.97
Rituximab	1	2.20 (0.31-15.7)	0.43	0	No Estimate	
<b>Maintenance therapy</b>						
Azathioprine	36	1.07 (0.75-1.55)	0.70	33	1.97 (1.31-2.97)	0.001
Cyclosporine	69	1.11 (0.83-1.50)	0.49	50	1.62 (1.11-2.37)	0.01
Mycophenolate mofetil	114	1.00 (0.74-1.34)	1.00	49	0.52 (0.36-0.77)	0.001
Mammalian target of rapamycin inhibitor	6	0.58 (0.26-1.32)	0.20	4	0.67 (0.25-1.83)	0.44
Corticosteroids	168	1.64 (1.01-2.66)	0.05	92	1.01 (0.59-1.71)	0.98
Tacrolimus	85	0.71 (0.53-0.94)	0.02	42	0.54 (0.36-0.79)	0.002
<b>Combination therapy</b>						
Tacrolimus or mycophenolate mofetil without cyclosporine or azathioprine	77	Reference		48	Reference	
Cyclosporine or azathioprine without tacrolimus or mycophenolate mofetil	109	1.29 (0.97-1.73)	0.09	39	2.21 (1.45-3.37)	<0.001
Other medication combinations	0	No Estimate		21	1.29 (0.77-2.16)	0.32
<b>Medication exposures adjusted for calendar year of transplant</b>						
<b>Induction therapy</b>						
Corticosteroids	116	0.98 (0.72-1.33)	0.91	68	1.34 (0.89-2.02)	0.16
Polyclonal antibody	41	1.03 (0.72-1.47)	0.88	22	1.03 (0.64-1.68)	0.90
Monoclonal antibody (OKT3)	6	0.63 (0.28-1.43)	0.27	11	1.95 (1.03-3.72)	0.04
Campath	3	0.50 (0.16-1.59)	0.24	4	1.39 (0.50-3.89)	0.53
IL-2 receptor antagonist	42	1.29 (0.90-1.83)	0.16	20	1.26 (0.76-2.11)	0.37
Rituximab	1	2.36 (0.33-17.0)	0.39	0	No Estimate	
<b>Maintenance therapy</b>						
Azathioprine	36	1.18 (0.77-1.82)	0.45	33	1.30 (0.76-2.25)	0.34
Cyclosporine	69	1.10 (0.77-1.57)	0.61	50	1.22 (0.75-1.97)	0.43
Mycophenolate mofetil	114	0.96 (0.68-1.36)	0.84	49	0.67 (0.42-1.09)	0.11
Mammalian target of rapamycin inhibitor	6	0.59 (0.26-1.34)	0.21	4	0.82 (0.30-2.25)	0.70

Corticosteroids	168	1.55 (0.95-2.55)	0.08	92	0.88 (0.51-1.51)	0.64
Tacrolimus	85	0.71 (0.52-0.99)	0.04	42	0.66 (0.42-1.05)	0.08
<b>Combination therapy</b>						
Tacrolimus or mycophenolate mofetil without cyclosporine or azathioprine	77	Reference		48	Reference	
Cyclosporine or azathioprine without tacrolimus or mycophenolate mofetil	109	1.39 (0.97-2.00)	0.07	39	1.62 (0.87-3.04)	0.13
Other medication combinations	0	No Estimate		21	1.30 (0.73-2.29)	0.37

Abbreviations:

IRR – Incidence rate ratio

CI – Confidence interval